Ocular Therapeutix Target Raised as FDA Path for AXPAXLI Clears

Key Facts

1H.C. Wainwright increased the price target for Ocular Therapeutix from $21 to $25, maintaining a Buy rating.

2The probability of approval for AXPAXLI was raised to 75% following alignment with the FDA.

In a move reflecting growing optimism in the biotech sector, H.C. Wainwright has increased its price target for Ocular Therapeutix from $21 to $25 while maintaining a Buy rating. This adjustment follows the company's successful alignment with the FDA regarding the New Drug Application (NDA) submission pathway for AXPAXLI. Consequently, the probability of approval for the drug, designed to treat wet age-related macular degeneration, has been raised to 75%.

These positive projections arrive as the specialty pharmaceuticals sector seeks to navigate market volatility, with analysts citing a potential 165% upside from current levels. Compared to peers in the ophthalmology space, Ocular stands out due to its clinical progress, competing in a market where giants like Regeneron reported strong Eylea sales in the most recent quarter per market data. This clear regulatory path significantly strengthens the company's competitive position in the expanding retinal treatment market.

Regarding stock performance, OCUL stood at $9.43 at close June 18, 2026, with a daily range between $9.37 and $10.39 according to market data. Investors are closely monitoring upcoming updates regarding the final regulatory submission timeline. Additionally, global markets are awaiting key economic data, including inflation rates from the UK and EU on June 17, which may influence risk appetite across the growth and biotech sectors.